Deucravacitinib in the Treatment of Cicatricial Alopecias

ConditionsCentral Centrifugal Cicatricial Alopecia Frontal Fibrosing Alopecia

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorIcahn School of Medicine at Mount Sinai

About this trial

This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants of any gender, age 18 years or older, at the time of informed consent at Screening

Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.

Participant self-reports a history of at least 6 months of moderate-to-severe CA (FFA or CCCA). Diagnosis will be made clinically, and severity assessed with according to the FFASI32 ≥30 and/or CHLG ≥3.

Participant has a negative Tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at screening or within the last 12 months.

Disqualifiers

Participant's cause of hair loss is indeterminable and/or they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.

Participant has a history of CA for > 5 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.

Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening. Deucravacitinib in the Treatment of Cicatricial Alopecias October 23, 2025.

Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).

Trial design

Design model

Parallel

Treatments tested in this trial

Deucravacitinib
Drug
6mg twice-daily oral treatment for 48 weeks.

Treatment groups

20 Participants

are divided into 2 treatment groups

Group A: Central Centrifugal Cicatricial AlopeciaExperimental treatment 1 intervention

Group B: Frontal Fibrosing AlopeciaExperimental treatment 1 intervention